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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.012Mucosal vaccines are thought to confer superior protection against mucosal infectious diseases. In
addition, mucosal routes of vaccine delivery preferentially induce the generation of T helper 17 (Th17)
cells, which produce the cytokine IL-17. Th17 cells are critical in mediating vaccine-induced immunity
against several mucosal infectious diseases. However, IL-17 is also a potent proinﬂammatory cytokine,
and we recently showed that IL-17 mediates immunopathology and lung injury after inﬂuenza infection
in mice. In the present study, we tested the hypothesis that mucosal pre-exposure to Th17-inducing
adjuvants can promote disease exacerbation upon subsequent infection with inﬂuenza virus. Mice
mucosally pre-exposed to Th17-inducing adjuvants, such as type II heat-labile enterotoxin or cholera
toxin, resulted in increased morbidity and exacerbated lung inﬂammation upon subsequent infection
with inﬂuenza virus. Furthermore, the increased morbidity was accompanied by increased expression of
inﬂammatory chemokines and increased accumulation of neutrophils. Importantly, blockade of the
IL-17 pathway in mice pre-exposed to Th17-inducing adjuvants resulted in attenuation of the in-
ﬂammatory phenotype seen in inﬂuenza-infected mice. Our ﬁndings indicate that, before mucosal
Th17-inducing adjuvants can be used in vaccine strategies, the short- and long-term detrimental
effects of such adjuvants on disease exacerbation and lung injury in response to infections, such as
inﬂuenza, should be carefully studied. (Am J Pathol 2014, 184: 55e63; http://dx.doi.org/10.1016/
j.ajpath.2013.09.012)Supported by NIH grants R01AI083541 and R01HL105427 (S.A.K.),
R01HL107380 (J.F.A.), R01DE013833 (T.D.C.), and U19-AI091036
(J.R.M.); by the Children’s Hospital of Pittsburgh; and by funds of the
Department of Medicine, University of Rochester (J.R.M.).
Disclosure: The IL-17R knockout mice and IL-17RA blocking antibody
used in this study were provided by Amgen.Mucosal vaccines are thought to induce better mucosal
immunity and to confer superior protection against mucosal
infectious diseases, compared with systemic routes of immu-
nization.1 This is consistent with the ﬁnding that mucosal
routes of vaccine delivery preferentially induce the generation
of T helper 17 (Th17) cells, which produce the cytokine
IL-17.2e5 Accordingly, Th17 cells are implicated as key
players in mediating vaccine-induced immunity against a va-
riety ofmucosal infectious diseases, including tuberculosis,5,6
bacterial pneumonia,7e9 pertussis (whooping cough),10,11 and
inhalational anthrax.4 However, IL-17 is also a potent proin-
ﬂammatory cytokine implicated in several inﬂammatory
autoimmune diseases, as well as in models of tissue injury.12
For example, acute lung injury is a severe clinical statestigative Pathology.
.characterized by noncardiogenic pulmonary edema, capillary
leak, and hypoxemia that can be caused by both infectious
and noninfectious stimuli, often observed as acute respiratory
distress syndrome. The primary mediator of the inﬂammation
associated with acute lung injury is rapid recruitment of
neutrophils and induction of damaging reactive oxygen
species intermediates. In this regard, our research group
recently showed that, in response to inﬂuenza infection,
Gopal et alIL-17 produced by gd T cells mediates immunopathology
and lung injury.13 In the present study, we tested the hy-
pothesis that mucosal pre-exposure to Th17-inducing adju-
vants in mice can promote disease exacerbation upon
subsequent inﬂuenza infection.
Herewe report thatmucosal pre-exposure to Th17-inducing
adjuvants, such as type II heat-labile enterotoxin5 or cholera
toxin,4 results in increased morbidity and exacerbated lung
inﬂammation upon subsequent infection with different inﬂu-
enzaA strains. A key role for IL-17 inmediating inﬂammation
in the lung is through induction of proinﬂammatory chemo-
kines that mediate accumulation of neutrophils.12 In accord,
the increased inﬂammation seen in the present study in the
lungs of mucosally pre-exposed, inﬂuenza-infected mice was
accompanied by increased expression of the inﬂammatory
chemokines CXCL1, CXCL9, CXCL10, and CCL2 and
increased accumulation of neutrophils. Importantly, we show
that the observed exacerbated inﬂammatory phenotype and
neutrophil accumulation due to mucosal pre-exposure to
Th17-inducing adjuvants are IL-17 pathwayedependent,
because treatment with IL-17 receptor blocking antibodies or
use of IL-17 receptor knockout mice attenuated the inﬂam-
matory phenotype. These ﬁndings thus indicate that, before
mucosal delivery of experimental Th17-inducing adjuvants
can be used in vaccine strategies, the detrimental effects on
disease exacerbation and lung injury to subsequent infections,
including inﬂuenza, should be carefully studied.
Materials and Methods
Animals
C57BL/6 wild-type mice were purchased from Taconic
Farms (Hudson, NY). IL-17 receptor A (IL-17RA) deﬁcient
mice14 were bred and maintained at the University of Pitts-
burgh. Age- and sex-matched mice between the ages of 6 to 8
weeks were infected in accordance with University of Pitts-
burgh Institutional Animal Care and Use Committee
guidelines.
Mucosal Immunization and Inﬂuenza Infection
Unanesthetized mice were vaccinated intranasally with 50
mL of PBS containing 1 mg type II heat-labile enterotoxin
(LT-IIb) or 1 mg cholera toxin (CT)5 (Sigma-Aldrich, St.
Louis, MO) or PBS alone. On day 3 after immunization,
mice were infected with 100 plaque-forming units (PFU) of
H1N1 inﬂuenza strain A Puerto Rico/8/1934 (A/PR/8/34) in
50 mL of PBS by oropharyngeal aspiration15 or were
intranasally infected with 1  106 PFU of a novel H1N1
inﬂuenza strain (A/California/7/2009)16 or 5  103 PFU of a
highly pathogenic H5N1 inﬂuenza strain (A/Vietnam/1203/
2004) in 50 mL of PBS.17 The infective dose used was
speciﬁc for each virus strain and was determined as the dose
that resulted in moderate weight loss and lung injury. In
some experiments, mice were treated intraperitoneally with56either 500 mg of IL-17RA blocking antibody (aIL-17RA) (a
kind gift from Amgen, Thousand Oaks, CA) or isotype
control (Bio X Cell, West Lebanon, NH), once a week,
starting from the day of infection. In some experiments, 133
mg of 6 kDa early secretory antigenic target (ESAT-61-20)
peptide was mixed with 1 mg LT-IIb holotoxin, and 50 mL
was used for intranasal immunization.
Flow Cytometry
Lung cell suspensions were prepared for ﬂow cytometry as
described previously.5 Single-cell suspensions were stained
with ﬂuorochrome-labeled antibodies, collected, and anal-
yzed as described previously.5 Cells were gated on IL-17e
producing Thy1.1 expressing lymphocytes,18 and the
numbers of IL-17eproducing ab T cells and gd T cells
were calculated.
Immunohistochemical Analysis
Lung lobes were instilled with 10% neutral buffered formalin
and embedded in parafﬁn. Lung sections were stained with
H&E stain, and inﬂammatory features were evaluated by
light microscopy at the University of Pittsburgh Research
Histology Core facility. For immunoﬂuorescent staining,
formalin-ﬁxed lung sections were processed as described
previously.5 Sections were probed with biotinylated rat
antieGr-1 (BD Pharmingen, San Diego, CA) to detect neu-
trophils in the inﬂammatory lesions as described previously.5
In Situ Hybridization
Parafﬁn-embedded tissue specimens were processed as
described previously.19 In situ hybridization with 35S-
labeled riboprobes against different chemokine mRNAs was
performed as described previously.5
qPCR
For quantitative real-time PCR (qPCR), lung tissue from
infected and control mice was homogenized and frozen in
RLT buffer (Qiagen, Valencia CA). Extraction of RNA,
reverse transcription, and ampliﬁcation were performed
as described previously,5 and mRNA levels relative to
GAPDH were calculated. Primer and probes sequences
were as described previously.20,21 Inﬂuenza burden was
determined by real-time reverse-transcription PCR (RT-
qPCR) for viral M protein mRNA, as described previously.13
Determination of Protein Levels
Protein levels of cytokines and chemokines were measured
in lung homogenates using a mouse Luminex assay (Linco;
EMD Millipore, Billerica, MA). Myeloperoxidase chlori-
nation and peroxidase activity were determined in lung
homogenates using an Invitrogen myeloperoxidase activity
assay kit (Life Technologies, Carlsbad, CA).ajp.amjpathol.org - The American Journal of Pathology
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Comparison of means between sample groups was per-
formed with the two-tailed Student’s t-test using GraphPad
Prism software version 5 (GraphPad Software, La Jolla,
CA). Differences were considered signiﬁcant at P  0.05.
Results
Mucosal Pre-Exposure to LT-IIb Adjuvant Increases
Morbidity and Mortality after H1N1 Inﬂuenza A/PR/8/
34 Infection
LT-IIb, a potent and well-characterized mucosal adjuvant22
induces, when delivered along with a Mycobacterium
tuberculosisespeciﬁc antigen, the generation of lung resident
antigenespeciﬁc Th17 responses.5 Consistent with these
ﬁndings, when IL-17 Thy1.1 reporter mice18 were mucosally
pre-exposed toLT-IIb alongwith theM. tuberculosisespeciﬁc
peptide ESAT-61-20, an increase in IL-17 producing cells was
observed.Although themajority of the IL-17eproducing cells
were T cell receptor ab T cells, a discrete population of
IL-17eproducing gd T cells was also detected (Figure 1A).
Recently, our research group showed that, after inﬂuenza A/
PR/8/34 infection, IL-17 has a role to play in mediating lungFigure 1 Mucosal pre-exposure to LT-IIb adjuvant promotes increased morbidi
reporter mice were mucosally exposed to ESAT-61-20 peptide in combination with 1
producing abþ T cells and gdþ T cells were determined by ﬂow cytometry. B an
exposure, mice were infected with 100 PFU of H1N1 inﬂuenza strain A/PR/8/34 in
was calculated (B) or survival was monitored over time (C). D: CXCL1, CXCL9, CXCL1
mouse Luminex assay. E: Relative lung viral loads were determined by RT-qPCR of
*P  0.05, yP  0.005, and zP  0.0005.
The American Journal of Pathology - ajp.amjpathol.orgpathology in mice.13 In the present study, therefore, we
investigated whether mucosal pre-exposure to Th17-inducing
adjuvants, such as LT-IIb alone, has any effect after subse-
quent exposure to inﬂuenza infection, in which IL-17 is
implicated in mediating acute lung injury.13,23
LT-IIb adjuvant alone was delivered mucosally without any
antigen, followed by inﬂuenza infection. In C57BL/6 mice,
exposure mucosally to LT-IIb 3 days before inﬂuenza A/PR/8/
34 infection resulted in signiﬁcantly increased weight loss
(Figure 1B) and increased mortality (Figure 1C), compared
with control mice that were pretreated with PBS before inﬂu-
enza infection. Importantly, mice exposed to LT-IIb and then
infected with inﬂuenza strain A/PR/8/34 exhibited increased
morbidity. In addition, lung homogenates from mice exposed
to LT-IIb before inﬂuenza infection also exhibited increased
expression of the inﬂammatory chemokines CXCL1, CXCL9,
CXCL10, and CCL2 (Figure 1D). These inﬂammatory che-
mokines are typical of the cytokine storm associated with
increased morbidity seen during severe inﬂuenza infections in
humans,24,25 suggesting that mucosal pre-exposure to LT-IIb
induces exacerbated production of inﬂammatory chemokines
in the inﬂuenza-infected lung. In addition, levels of inﬂuenza
A/PR/8/34 M protein mRNA were increased in lungs of mice
exposed to LT-IIb and then infected with inﬂuenza, compared
with lungs of inﬂuenza-infected mice pre-exposed to PBSty and mortality after H1N1 inﬂuenza A/PR/8/34 infection. A: IL-17 Thy1.1
mg LT-IIb adjuvant. On day 6 after exposure, the numbers of Thy1.1þ IL-17-
d C: C57BL/6 mice were mucosally exposed to 1 mg LT-IIb. On day 3 after
50 mL of PBS. Mice were weighed every day, and percentage weight change
0, and CCL2 protein levels were determined from lung homogenates using a
viral M protein mRNA. Data are expressed as means  SD. nZ 4 or 5 mice.
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Gopal et alalone (Figure 1E). These ﬁndings suggest that mice pre-
exposed to LT-IIb displayed increased susceptibility to A/
PR/8/34 virus infection.
Mucosal Pre-Exposure to LT-IIb Adjuvant Promotes
Lung Pathology after Inﬂuenza A/PR/8/34 Infection
Because our ﬁndings suggested that mucosal pre-exposure to
Th17-inducing adjuvants increase morbidity and promote
disease progression after inﬂuenza infection, we next58investigated whether the increased morbidity seen in mice
exposed to LT-IIb and then infected with inﬂuenza is associ-
ated with increased pathological responses. Mice exposed to
LT-IIb and then infectedwithA/PR/8/34virus exhibited severe
inﬂammation in the lung as observed on H&E stained lung
sections (Figure 2, A and B), which coincided with increased
localization of mRNA for inﬂammatory chemokines such as
CXCL9 and CXCL10 within the inﬂamed lung (Figure 2, C
and D). The increased inﬂammation observed in inﬂuenza-
infected mice pre-exposed to LT-IIb coincided withajp.amjpathol.org - The American Journal of Pathology
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inﬂamed lungs, compared with control PBS pretreated,
inﬂuenza-infected lungs (Figure 2E). Taken together, these
ﬁndings indicate that mucosal pre-exposure to Th17-inducing
adjuvants can have detrimental effects and may promote dis-
ease progression upon subsequent exposure to viral infections.
To address the window of susceptibility after mucosal
exposure to Th17 adjuvants within which the detrimental
effects are sustained, we exposed mice with LT-IIb either 3,
7, or 15 days before inﬂuenza infection. The effect of
increased susceptibility to inﬂuenza infection in pre-exposed
mice was retained for 3 and 7 days after LT-IIb exposure,
but was lost by 15 days after LT-IIb exposure (Figure 2F).
Consistent with this ﬁnding, mice exposed to LT-IIb either 3
or 7 days before inﬂuenza infection exhibited considerably
worsened lung pathology, whereas mice exposed to LT-IIb
15 days before inﬂuenza infection did not demonstrate
increased lung pathology (Figure 2G). Taken together, these
ﬁndings suggest that the detrimental effects of LT-IIb
exposure on inﬂuenza infection are short-lived.Mucosal Pre-Exposure to Th17-Inducing Adjuvants
Mediates Increased Pathology after Novel Pandemic
H1N1 Inﬂuenza Infection
CT, another potent mucosal adjuvant, induces Th17 responses
after intranasal delivery.2 When used in an irradiated spore
vaccine, CT confers protective responses against inhalational
anthrax.4 Next, therefore, we investigated whether the ability to
drive inﬂammatory responses on inﬂuenza infection is limited
to LT-IIb, orwhethermucosal exposure to other Th17-inducing
adjuvants (such as CT4) can also similarly induce exacerbated
inﬂammation and increasedmorbidity upon inﬂuenza infection.
C57BL/6 mice mucosally pre-exposed to either CT or LT-IIb
lost signiﬁcantly more weight when infected with novel pan-
demic H1N1 inﬂuenza virus, compared with PBS pretreated,
H1N1 inﬂuenzaeinfected mice (Figure 3A). The increased
weight loss observed in CT and LT-IIb pre-exposed, H1N1
inﬂuenzaeinfected mice also coincided with increased
inﬂammation in the lungs stained with H&E (Figure 3B),
increased mRNA expression of CXCL9 (Figure 3C), and
increased accumulationofGr1þ neutrophilswithin the inﬂamed
lung (Figure 3, D and E). The activity of myeloperoxidase, an
enzyme associated with neutrophil activation and generation of
reactiveoxygen species leading to oxidative damage,26was also
increased signiﬁcantly in lungs of H1N1 inﬂuenzaeinfectedFigure 2 Mucosal pre-exposure to LT-IIb adjuvant promotes lung pathology a
exposed to 1 mg LT-IIb or PBS and 3 days later were infected with 100 PFU of H1N
lung sections were stained with H&E, and the percentage of lung affected by inﬂa
inﬂammation. C and D: FFPE lung sections were assayed for CXCL9 (C) and CXCL1
murine chemokine mRNA probes. The arrows and arrowheads indicate expression o
by immunoﬂuorescence using antibodies speciﬁc for Gr1 (red). The numbers of Gr1
to 1 mg LT-IIb or PBS and 3, 7, or 15 days later were infected with 100 PFU of H1N
over time. G: FFPE lung sections were stained with H&E for assessment of inﬂamm
0.005, and zP  0.0005. Original magniﬁcation: 40 (BeD); 100 (E, upper row
The American Journal of Pathology - ajp.amjpathol.orgmice pre-exposed to LT-IIb and CT, compared with PBS pre-
treated, H1N1 inﬂuenzaeinfected control mice (Figure 3F).
Taken together, these ﬁndings demonstrate that mucosal pre-
exposure to Th17-inducing adjuvants, such as LT-IIb and CT,
mediates inﬂammatory pathological responses upon subse-
quent inﬂuenza infection.
IL-17 Induced by Mucosal Pre-Exposure to
Th17-Inducing Adjuvants Mediates Pathology after
Inﬂuenza Infection
To deﬁnitively address whether the increased morbidity due
to mucosal pre-exposure to Th17-inducing adjuvants after
inﬂuenza infection is IL-17 pathway dependent, mice muco-
sally exposed to either LT-IIb or CT adjuvant were subse-
quently infected with the highly pathogenic H5N1 inﬂuenza
virus and then received either isotype control antibody or
IL-17RA blocking antibody. Similar to our results with
inﬂuenzaA/PR/8/34 and pandemicH1N1 inﬂuenza infection,
mice mucosally exposed to CT or LT-IIb and then infected
with H5N1 inﬂuenza virus lost signiﬁcantly more weight
(Figure 4, A and B) and exhibited severe lung inﬂammation
(Figure 4C), which coincided with increased neutrophil
accumulation within the inﬂamed lung (Figure 4, D and E).
Importantly, the increased weight loss, increased lung
inﬂammation, and increased neutrophil accumulation seen in
inﬂuenza-infected mice mucosally pre-exposed to LT-IIb or
CT was signiﬁcantly attenuated when the mice were treated
with IL-17RA blocking antibody (Figure 4, AeE). Similarly,
IL-17RA knockout mice exposed to LT-IIb and then infected
with H1N1 inﬂuenza virus also demonstrated reduced weight
loss (Figure 4F), decreased lung inﬂammation (data not
shown), and decreased neutrophil accumulation (Figure 4G),
compared with LT-IIb pre-exposed, H1N1 inﬂuenza-infected
control mice. Interestingly, although the viral titers in
mucosally pre-exposedmice trended toward being higher, the
overall titers did not differ signiﬁcantly between the groups
(data not shown). Taken together, these ﬁndings indicate that
mucosal pre-exposure to Th17-inducing adjuvants mediates
exacerbates lung inﬂammation after inﬂuenza infection in an
IL-17 pathwayedependent manner.
Discussion
The emerging consensus is that mucosal vaccines are likely
to induce better mucosal immunity and to confer superiorfter H1N1 inﬂuenza A/PR/8/34 infection. A: C57BL/6 mice were mucosally
1 inﬂuenza strain A/PR/8/34. B: Formalin-ﬁxed, parafﬁn-embedded (FFPE)
mmation was scored on a scale from 0% to 100%, based on the severity of
0 (D) mRNA localization by in situ hybridization, using the corresponding
f CXCL9 and CXCL10 mRNA, respectively. E: FFPE lung sections were analyzed
þ cells per20 ﬁeld were counted. F: C57BL/6 mice were mucosally exposed
1 inﬂuenza strain A/PR/8/34. Weight loss was monitored in individual mice
ation. Data are expressed as means  SD. nZ 4 to 8 mice. *P  0.05, yP 
); 200 (E, lower row).
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Figure 3 Mucosal pre-exposure to Th17-
inducing adjuvants mediates increased pathology
after novel pandemic H1N1 inﬂuenza infection. A:
C57BL/6mice weremucosally exposed to 1mg LT-IIb,
1 mg CT, or PBS. On day 3 after exposure, mice were
infected with 1  106 PFU of novel H1N1 inﬂuenza
strain A/California/7/2009. Percentage weight
change was determined in individual mice over time.
BeD: FFPE lung sections were stained with H&E (B)
or were assayed for CXCL9mRNA localization (arrows)
by in situ hybridization using a murine CXCL9 mRNA
probe (C), and Gr1-accumulating neutrophils were
detected by immunohistochemistry (D). E: The
numbers of Gr1þ cells per20 ﬁeld were counted. F:
The levels of myeloperoxidase activity (MPO) were
determined in lung homogenates. Data are expressed
as means  SD. nZ 4 or 5 mice. *P  0.05, yP 
0.005, and zP 0.0005. Original magniﬁcation:40
(B and C); 200 (D).
Gopal et alprotection against infectious diseases, compared with con-
ventional systemic routes of immunization.1 In addition, the
identiﬁcation of the new subset of CD4þ Th17 cells as key
players in vaccine-induced immunity against a variety of
mucosal infectious diseases5e11 suggests that incorporation
of Th17 mucosal adjuvants into vaccine strategies targeting
mucosal infectious diseases would be beneﬁcial. However,
IL-17 is a potent proinﬂammatory cytokine implicated as a
key player contributing to inﬂammation and tissue injury.12
Thus, the successful development of Th17 mucosal60adjuvants for use in humans will require the generation of
tightly controlled antigen-speciﬁc Th17 cell responses
without induction of the nonspeciﬁc IL-17edependent in-
ﬂammatory responses.
Our research group has previously demonstrated that
delivery of M. tuberculosis antigens in LT-IIb adjuvant in-
duces a persistent lung-resident Th17 population that is
protective upon subsequent challenge with M. tuberculosis
even 100 days later.5 Thus, mucosal vaccines with Th17-
inducing adjuvants are prime candidates for inclusion inajp.amjpathol.org - The American Journal of Pathology
Figure 4 The IL-17 pathway mediates pathology in mice mucosally exposed to Th17-inducing adjuvants and then infected with inﬂuenza virus. A and B:
C57BL/6 mice were mucosally exposed to 1 mg LT-IIb, 1 mg CT, or PBS. On day 3 after immunization, mice were infected with 5  103 PFU of the highly
pathogenic H5N1 inﬂuenza strain A/Vietnam/1203/2004. From day 0 of inﬂuenza infection, mice were treated with isotype control antibody or with 500 mg
IL-17RA neutralizing antibody (aIL-17R). Percentage weight change was determined over time. Both LT- and CT-treated mice were compared with the same
PBS-treated mice. C and D: FFPE lung sections were stained with H&E (C) or were analyzed by immunoﬂuorescence using antibodies speciﬁc for Gr1 (red) (D).
E: The numbers of Gr1þ cells per 20 ﬁeld were counted. F: C57BL/6 (B6) or IL-17RA knockout mice were mucosally exposed to 1 mg LT-IIb or PBS. On day 3
after immunization, mice were infected with 1  106 PFU of novel H1N1 inﬂuenza strain A/California/7/2009, and weight loss was monitored in individual
mice over time. G: FFPE lung sections were analyzed by immunoﬂuorescence using antibodies speciﬁc for Gr1. The numbers of Gr1þ cells per 20 ﬁeld were
counted. Data are expressed as means  SD. nZ 4 or 5 mice. *P  0.05, yP  0.005, and zP  0.0005. Original magniﬁcation,40 (C); 100 (D, upper row);
200 (D, lower row).
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Gopal et alfuture vaccine strategies against global infectious diseases,
such as tuberculosis. However, the ﬁndings presented here
show that ongoing adjuvant-induced IL-17 responses may
promote inﬂammation and exacerbate disease progression if
such mucosally exposed individuals subsequently become
infected with inﬂuenza A, in which IL-17 plays a patho-
logical rather than protective role. Thus, the present ﬁndings
indicate the importance of examining long-term protective
vaccine-induced responses induced by Th17-inducing mu-
cosal adjuvants, along with short-term detrimental effects of
vaccine-induced IL-17 responses to infections, including
inﬂuenza.
Recently, several adjuvants, including oil-in-water nano-
emulsions,27 CT,2,4 polyelectrolyte microcapsules,28 heat-
labile enterotoxins (such as LT-IIb),5 and heat-killed
Klebsiella pneumoniae,9 have been shown to induce potent
Th17 responses when delivered mucosally. The ability of
these mucosal adjuvants to drive the generation of potent
long-term persisting antigen-speciﬁc IL-17eproducing ab T
cells is critical for the protection induced by the vaccine, and
so the mucosal route of vaccination in combination with an
appropriate mucosal adjuvant can be an effective strategy to
induce lung-resident vaccine-induced Th17 responses.
However, the present ﬁndings and those of other studies
show that innate cells, such as gd T cells, are also activated by
these adjuvants and produce IL-17.29 IL-17 produced by
either adaptive or innate immune cells can lead to immediate
inﬂammation upon subsequent infections, including inﬂu-
enza. Our research group has shown that, during inﬂuenza
A/PR/8/34 infection, the IL-17 pathway plays a role in
immunopathology; mice deﬁcient in IL-17 signaling exhibit
lesser morbidity, reduced levels of oxidized phospholipids,
and decreased lung inﬂammation, compared with wild-type
inﬂuenza-infected mice.13 A more recent study similarly
demonstrated that infection with pandemic H1N1 inﬂuenza
infection in IL-17edeﬁcient mice resulted in reduced acute
lung injury.23 Interestingly, in that study elevated levels of
IL-17 were also found in mild, hospitalized, and critical
groups of patients who were conﬁrmed positive for H1N1
inﬂuenza A 2009 virus in Beijing.23
A Th17 hypercytokinemia signature was observed in in-
dividuals severely infected with inﬂuenza in whom high
levels of CCL2, CXCL9, and CXCL10 were detected.24,25
Our research group previously reported that IL-17 respon-
sive elements are detected in the promoter regions of both
CXCL9 and CXCL10, and that IL-17 can induce expression
of these chemokines.6,19 In addition, IL-17 can induce
CCL2 production and mediate macrophage recruitment and
emphysema in response to cigarette smoke in the lung.30
Thus, the induction of Th17-dependent chemokines such
as CXCL9, CXCL10, and CCL2 in mucosally pre-exposed,
inﬂuenza-infected mice in the present study parallels ﬁnd-
ings from human studies in which Th17 mediators are
associated with more severe disease.24,25 In the present
study, the detrimental effects of Th17-inducing adjuvants
were short-lived, and it is possible that the inﬂammatory62effects of mucosal delivery of Th17-inducing adjuvants
wane over time. Because we delivered mucosal adjuvant
alone, prior to inﬂuenza infection, we believe that the in-
ﬂammatory effects mediated by the adjuvant are likely
dependent on responsive innate cells producing IL-17 and
are short-lived. Before incorporation of Th17 adjuvants into
mucosal vaccine strategies, studies should be conducted
to speciﬁcally address whether the adjuvant induces any
detrimental short- or long-term effects against subsequent
infections, including inﬂuenza.
In summary, the present study demonstrates that mucosal
pre-exposure to Th17-inducing adjuvants can induce short-
term detrimental effects upon subsequent exposure to
stimuli such as inﬂuenza infection, highlighting the impor-
tance of studying both short-term and long-term effects of
Th17-inducing mucosal adjuvants in health and disease.Acknowledgments
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